Table 2.
Types of vaccines received and time interval between doses in PWH without vs. with BTI.
| Breakthrough Infection No |
Breakthrough Infection Yes |
p | |
|---|---|---|---|
| Types of COVID-19 vaccines received, doses 1 and 2, n (%) | 0.004 | ||
| mRNA–mRNA | 182 (89.7) | 71 (76.3) | |
| ChAdOx1–mRNA | 13 (6.4) | 9 (9.7) | |
| ChAdOx1–ChAdOx1 | 7 (3.4) | 12 (12.9) | |
| Janssen/Novavax | 1 (0.5) | 1 (1.1) | |
| Types of COVID-19 vaccines received, dose 3, n (%) | 0.929 | ||
| Unknown/received only 2 doses | 34 | 13 | |
| BNT162b2 | 67 (67/163, 41.1) | 32 (32/79, 40.5) | |
| mRNA-1273 | 96 (96/163, 58.9) | 47 (47/79, 59.5) | |
| Number of vaccine doses received at the time of BTI, n (%) | - | ||
| 2 | - | 25 (26.9) | |
| 3 | - | 59 (63.4) | |
| 4 | - | 9 (9.7) | |
| Number of days since last vaccine dose (IQR) | - | 127.5 (67, 176) | - |
| Number of days since second dose (for persons who develop BTI between second and third doses) (n = 25) | 168 (135, 182) | ||
| Number of days since third dose (for persons who develop BTI between third and fourth doses) (n = 59) | 108 (55, 167) | ||
| Follow-up time from dose 2 to study end or BTI, months (median, IQR) | 14.0 (11.5, 17.3) | 8.8 (6.1, 10.9) | <0.001 |
| Follow-up time from third dose (for those who did not have BTI prior to third dose) | 8.8 (6.1, 12.4) | 3.9 (1.9, 5.7) | <0.001 |
| Follow-up time from fourth dose (for those who did not have BTI prior to fourth dose) | 1.6 (1.0, 3.3) | 0.6 (0.3, 1.4) | 0.017 |
Comparisons were based on Chi-square test or Fisher’s exact test as appropriate. Other continuous variables, were compared between groups using Wilcoxon rank sum test.